HCAT Stock Analysis: Buy, Sell, or Hold?
HCAT - Health Catalyst, Inc Common Stock
$1.17
-0.17 (-12.69%)
▼
5d:
-26.42%
30d:
-4.88%
90d:
-36.41%
WAIT
LOW Confidence
Analysis Updated: May 14, 2026 12:00 AM ET
Earnings: May 11, 2026
0d
Get Alerted When HCAT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: HCAT is down 26.4% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: HCAT is down 26.4% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: HCAT is currently trading at $1.17, which is considered slightly low relative to its 30-day fair value range of $1.13 to $1.48. From a valuation perspective, the stock is trading at a premium (Forward PE: 9.2) compared to its historical average (6.8). At these levels, the market is pricing in 10.9% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, HCAT is in a strong downtrend. The price is currently testing key support at $1.15. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 12.7% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $1.75 (+49.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, HCAT is in a strong downtrend. The price is currently testing key support at $1.15. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 12.7% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $1.75 (+49.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$1.13 -
$1.48
Company Quality Score
52/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
73.8%
Protect Your Profits
Holding HCAT? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-12.7%)
- BULLISH: Trading 49.6% below Wall St target ($1.75)
- NEUTRAL: Trading at premium valuation - market expects 10.9% growth which is achievable
- WARNING: Recommendation downgraded due to -26.4% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$1.13 -
$1.48
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$1.15
Resistance Level
$1.77
Current Trend
Strong Downtrend
Technical data as of
May 14, 2026
Fundamental Context
Forward P/E (Next Year Est.)
9.24
Wall Street Target
$1.75
(+49.6%)
Revenue Growth (YoY)
-10.9%
Profit Margin
-87.7%
Valuation Premium vs History
+10.9% premium
PE vs Historical
9.2 vs 6.8
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+10.9%
(market-implied from PE analysis)
1-Year Target
$1.30
(+11%)
2-Year Target
$1.44
(+23%)
3-Year Target
$1.60
(+36%)
3-Yr Target (if PE normalizes)
(PE: 9→7)
PE COMPRESSION
$1.17
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.0, Growth: 133.6%)
$9.42
(+705%)
Base:
(SPY PE: 9.2, Growth: 133.6%)
$3.95
(+238%)
Bear:
(PE: 6.8, Growth: 133.6%)
$2.91
(+148%)
Share & Embed Analysis
Last updated: May 15, 2026 4:27 AM ET
Data refreshes hourly during market hours. Next update: 5:27 AM
Data refreshes hourly during market hours. Next update: 5:27 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is HCAT showing a specific setup today?
Insider Activity (6 Months)
0
Buys
2
Sells
Net
INSIDERS SELLING
Recent Transactions
Benjamin Landry
SELL
27425 shares
2025-12-05
Julie Larson-Green
SELL
47997 shares
2025-12-04
Top Rated Health Information Services Stocks
Top-rated stocks in Health Information Services by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
VEEV
Veeva Systems Inc Class A |
BUY
32 analysts |
$264 | 55 HOLD |
|
PRVA
Privia Health Group Inc |
STRONG BUY
21 analysts |
$32 | 57 HOLD |
|
GEHC
GE HealthCare Technologi… |
STRONG BUY
21 analysts |
$90 | 60 HOLD |
|
PHR
Phreesia Inc |
STRONG BUY
15 analysts |
$16 | 54 HOLD |
|
EVH
Evolent Health Inc |
STRONG BUY
14 analysts |
$5 | 60 HOLD |
Advanced HCAT Option Strategies
Professional options setups generated by AI based on today's HCAT price and gamma walls.
